Nevro Announces FDA Submission for HF10® Therapy in Patients with Painful Diabetic Neuropathy
SENZA-PDN Study is Largest Prospective, Multicenter, Randomized Clinical Trial of Spinal Cord Stimulation Conducted to Date REDWOOD CITY, Calif., Dec. 28, 2020 /PRNewswire/ — Nevro Corp. (NYSE: NVRO), a global…